Votrient is a cancer medication that slows the growth of cancer cells and interferes with their spread in the body. It is a multiple kinase inhibitor used to treat kidney cancer and soft tissue sarcoma, a tumor that can develop in muscles, tendons, joints, or blood vessels. It is usually given after other cancer treatments have proven ineffective for soft tissue sarcoma.


Votrient may lower blood cells that help the body fight infection and make the blood clot more easily, making the body more susceptible to infection. It may also lead to: slow healing of a wound, dizziness, fainting, or a fast and pounding heartbeat, fever, chills, shortness of breath or nosebleed. The side effects are usually reversible and go away after therapy is complete.


Votrient appears to increase the risk of death among some patients. An estimated 1.5 out of every 100 patients given Votrient, or two other cancer drugs, Nexavar, and Sutent, die due to complications according to the Journal of Clinical Oncology. The most common fatal complication was bleeding, along with a higher risk for heart attack, heart failure or liver failure. Patents and exclusivity rights prevent generic Votrient from being manufactured in the U.S.